Applications of immunopharmacogenomics: Predicting, preventing, and understanding immune-mediated adverse drug reactions

Jason H. Karnes; Matthew A. Miller; Katie D. White; Katherine C. Konvinse; Rebecca K. Pavlos; Alec J. Redwood; Jonathan G. Peter; Rannakoe Lehloenya; Simon A. Mallal; Elizabeth J. Phillips

doi:10.1146/annurev-pharmtox-010818-021818

Applications of immunopharmacogenomics: Predicting, preventing, and understanding immune-mediated adverse drug reactions

Jason H. Karnes, Matthew A. Miller, Katie D. White, Katherine C. Konvinse, Rebecca K. Pavlos, Alec J. Redwood, Jonathan G. Peter, Rannakoe Lehloenya, Simon A. Mallal, Elizabeth J. Phillips

Research output: Contribution to journal › Review article › peer-review

42 Scopus citations

Abstract

Adverse drug reactions (ADRs) are a significant health care burden. Immune-mediated adverse drug reactions (IM-ADRs) are responsible for one-fifth of ADRs but contribute a disproportionately high amount of that burden due to their severity. Variation in human leukocyte antigen (HLA) genes has emerged as a potential preprescription screening strategy for the prevention of previously unpredictable IM-ADRs. Immunopharmacogenomics combines the disciplines of immunogenomics and pharmacogenomics and focuses on the effects of immune-specific variation on drug disposition and IM-ADRs. In this review, we present the latest evidence for HLA associations with IM-ADRs, ongoing research into biological mechanisms of IM-ADRs, and the translation of clinical actionable biomarkers for IM-ADRs, with a focus on T cell-mediated ADRs.

Original language	English (US)
Pages (from-to)	463-486
Number of pages	24
Journal	Annual review of pharmacology and toxicology
Volume	59
DOIs	https://doi.org/10.1146/annurev-pharmtox-010818-021818
State	Published - Jan 6 2019

Keywords

Adverse drug reaction
Human leukocyte antigen
Immunopharmacogenomics
Pharmacogenomics
Stevens-Johnson syndrome
Toxic epidermal necrolysis

ASJC Scopus subject areas

Toxicology
Pharmacology

Access to Document

10.1146/annurev-pharmtox-010818-021818

Cite this

Karnes, J. H., Miller, M. A., White, K. D., Konvinse, K. C., Pavlos, R. K., Redwood, A. J., Peter, J. G., Lehloenya, R., Mallal, S. A., & Phillips, E. J. (2019). Applications of immunopharmacogenomics: Predicting, preventing, and understanding immune-mediated adverse drug reactions. Annual review of pharmacology and toxicology, 59, 463-486. https://doi.org/10.1146/annurev-pharmtox-010818-021818

Karnes, JH, Miller, MA, White, KD, Konvinse, KC, Pavlos, RK, Redwood, AJ, Peter, JG, Lehloenya, R, Mallal, SA & Phillips, EJ 2019, 'Applications of immunopharmacogenomics: Predicting, preventing, and understanding immune-mediated adverse drug reactions', Annual review of pharmacology and toxicology, vol. 59, pp. 463-486. https://doi.org/10.1146/annurev-pharmtox-010818-021818

@article{bb0b624e36754747a2228fbab995c068,

title = "Applications of immunopharmacogenomics: Predicting, preventing, and understanding immune-mediated adverse drug reactions",

abstract = "Adverse drug reactions (ADRs) are a significant health care burden. Immune-mediated adverse drug reactions (IM-ADRs) are responsible for one-fifth of ADRs but contribute a disproportionately high amount of that burden due to their severity. Variation in human leukocyte antigen (HLA) genes has emerged as a potential preprescription screening strategy for the prevention of previously unpredictable IM-ADRs. Immunopharmacogenomics combines the disciplines of immunogenomics and pharmacogenomics and focuses on the effects of immune-specific variation on drug disposition and IM-ADRs. In this review, we present the latest evidence for HLA associations with IM-ADRs, ongoing research into biological mechanisms of IM-ADRs, and the translation of clinical actionable biomarkers for IM-ADRs, with a focus on T cell-mediated ADRs.",

keywords = "Adverse drug reaction, Human leukocyte antigen, Immunopharmacogenomics, Pharmacogenomics, Stevens-Johnson syndrome, Toxic epidermal necrolysis",

author = "Karnes, {Jason H.} and Miller, {Matthew A.} and White, {Katie D.} and Konvinse, {Katherine C.} and Pavlos, {Rebecca K.} and Redwood, {Alec J.} and Peter, {Jonathan G.} and Rannakoe Lehloenya and Mallal, {Simon A.} and Phillips, {Elizabeth J.}",

year = "2019",

month = jan,

day = "6",

doi = "10.1146/annurev-pharmtox-010818-021818",

language = "English (US)",

volume = "59",

pages = "463--486",

journal = "Annual review of pharmacology and toxicology",

issn = "0362-1642",

publisher = "Annual Reviews Inc.",

}

TY - JOUR

T1 - Applications of immunopharmacogenomics

T2 - Predicting, preventing, and understanding immune-mediated adverse drug reactions

AU - Karnes, Jason H.

AU - Miller, Matthew A.

AU - White, Katie D.

AU - Konvinse, Katherine C.

AU - Pavlos, Rebecca K.

AU - Redwood, Alec J.

AU - Peter, Jonathan G.

AU - Lehloenya, Rannakoe

AU - Mallal, Simon A.

AU - Phillips, Elizabeth J.

PY - 2019/1/6

Y1 - 2019/1/6

N2 - Adverse drug reactions (ADRs) are a significant health care burden. Immune-mediated adverse drug reactions (IM-ADRs) are responsible for one-fifth of ADRs but contribute a disproportionately high amount of that burden due to their severity. Variation in human leukocyte antigen (HLA) genes has emerged as a potential preprescription screening strategy for the prevention of previously unpredictable IM-ADRs. Immunopharmacogenomics combines the disciplines of immunogenomics and pharmacogenomics and focuses on the effects of immune-specific variation on drug disposition and IM-ADRs. In this review, we present the latest evidence for HLA associations with IM-ADRs, ongoing research into biological mechanisms of IM-ADRs, and the translation of clinical actionable biomarkers for IM-ADRs, with a focus on T cell-mediated ADRs.

AB - Adverse drug reactions (ADRs) are a significant health care burden. Immune-mediated adverse drug reactions (IM-ADRs) are responsible for one-fifth of ADRs but contribute a disproportionately high amount of that burden due to their severity. Variation in human leukocyte antigen (HLA) genes has emerged as a potential preprescription screening strategy for the prevention of previously unpredictable IM-ADRs. Immunopharmacogenomics combines the disciplines of immunogenomics and pharmacogenomics and focuses on the effects of immune-specific variation on drug disposition and IM-ADRs. In this review, we present the latest evidence for HLA associations with IM-ADRs, ongoing research into biological mechanisms of IM-ADRs, and the translation of clinical actionable biomarkers for IM-ADRs, with a focus on T cell-mediated ADRs.

KW - Adverse drug reaction

KW - Human leukocyte antigen

KW - Immunopharmacogenomics

KW - Pharmacogenomics

KW - Stevens-Johnson syndrome

KW - Toxic epidermal necrolysis

UR - http://www.scopus.com/inward/record.url?scp=85057352696&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85057352696&partnerID=8YFLogxK

U2 - 10.1146/annurev-pharmtox-010818-021818

DO - 10.1146/annurev-pharmtox-010818-021818

M3 - Review article

C2 - 30134124

AN - SCOPUS:85057352696

SN - 0362-1642

VL - 59

SP - 463

EP - 486

JO - Annual review of pharmacology and toxicology

JF - Annual review of pharmacology and toxicology

ER -

Applications of immunopharmacogenomics: Predicting, preventing, and understanding immune-mediated adverse drug reactions

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this